Attachment and fusion inhibitors potently prevent dendritic cell-driven HIV infection.
Attachment and fusion inhibitors potently prevent dendritic cell-driven HIV infection.
复制标题
附着和融合抑制剂有效防止树突状细胞驱动的HIV感染。
DOI:
10.1097/qai.0b013e3181ff2aa5
复制
发表时间:
2011-03-01
期刊:
影响因子:
--
通讯作者:
Robbiani M
中科院分区:
文献类型:
--
作者:
Frank I;Robbiani M
Dendritic cells (DCs) efficiently transfer captured (trans) or de novo produced (cis) virus to CD4 T cells. Using monocyte-derived DCs we evaluated entry inhibitors targeting HIV envelope (BMS-C, T-1249) or CCR5 (CMPD167) for their potency to prevent DC-infection, DC-driven infection in T cells in trans and cis, and direct infection of DC-T cell mixtures. Immature DC-T cultures with distinct mechanisms of viral transfer yielded similar levels of infection, and produced more proviral DNA compared to matched mature DC-T cultures or infected immature DCs. Although all compounds completely blocked HIV replication, 16 times more of each inhibitor (250 vs 15.6nM) was required to prevent low-level infection of DCs compared to the productive DC-T cell cocultures. Across all cell systems tested, BMS-C blocked infection most potently. BMS-C was significantly more effective than CMPD167 at preventing DC infection. In fact, low doses of CMPD167 significantly enhanced DC-infection. Elevated levels of CCL4 were observed when immature DCs were cultured with CMPD167. Viral entry inhibitors did not interfere with Candida albicans-specific DC cytokine/chemokine responses. These findings indicate that an envelope-binding small molecule is a promising tool for topical microbicide design to prevent the infection of early targets needed to establish and disseminate HIV infection.